Air Products & Chemicals
APD
$297.09
-2.22%
Air Products & Chemicals is a global industrial gas supplier operating in roughly 50 countries, producing and distributing atmospheric and process gases — oxygen, nitrogen, argon, hydrogen, and helium — alongside specialty gases and related equipment for customers in chemicals, energy, healthcare, metals, electronics, and refining. As the world's largest supplier of hydrogen and helium, the company occupies a structurally advantaged position in an oligopolistic industry dominated by long-term, take-or-pay contracts and on-site plants that create high switching costs and sticky revenue, distinguishing it from commodity chemical producers. The current investor narrative centers on the company's fiscal Q4 2026 earnings beat on higher volumes with raised guidance, reinforcing a recovery story after a turbulent stretch marked by multi-billion-dollar impairments in prior quarters tied to its large-scale clean hydrogen and blue ammonia megaprojects. A parallel thread is the geopolitical helium supply crisis stemming from Middle East conflict, which threatens semiconductor customers but simultaneously strengthens pricing power for APD as the industry's largest helium supplier — a dynamic that has kept the stock in focus for both cyclical-recovery and thematic-supply investors.…
APD
Air Products & Chemicals
$297.09
Related headlines
Investment Opinion: Should I buy APD Today?
Rating: Hold with a constructive bias. The core thesis is that APD's franchise is intact and the earnings recovery is real — Q4 2026 revenue of $3.556 billion grew 12.27% year over year and operating margin snapped back to 16.0% from -66.3% in Q3 — but at $316.53 the stock already discounts much of that normalization, leaving only 8.7% upside to the $344.10 average analyst target against a 13.1% downside to the $275 low target. The 15-Buy/9-Hold/0-Sell consensus (recommendation mean 1.92) confirms analysts like the business but are divided on how much execution risk remains in the clean hydrogen and blue ammonia megaprojects.
The supporting evidence is genuinely mixed. On the positive side, the forward PE of 20.4x on consensus EPS of $19.88 sits at the low end of APD's normalized 20x-27x band (Q1 2026 at 20.3x, Q2 2026 at 22.8x), gross margin has held in a tight 30.5%-32.8% range across the last four quarters, and roughly 47% of quarterly revenue ($1.671 billion of $3.556 billion) comes from contracted on-site take-or-pay plants. Against that, trailing free cash flow of just $476.8 million versus $4.2 billion of trailing capex produces a 0.77% FCF yield and a 301% payout ratio on a 2.59% dividend yield, debt-to-equity is 1.28 with total debt-to-capitalization at 56.1%, and the current ratio of 1.07 is thin. On sales and book the stock is not cheap: P/S of 4.77x and EV/sales of 6.95x sit well above the 1.5x-2.5x chemical norm, and P/B of 4.34x is near the top of APD's own 3.6x-4.9x range — the valuation case rests entirely on earnings normalization materializing.
The biggest risks that could invalidate the thesis are a renewed megaproject impairment (Q3 2026's $2.89 billion of other expenses produced a $1.441 billion loss and -66.3% operating margin), a helium-driven semiconductor demand slowdown that offsets APD's pricing power, and a dividend that is not covered by free cash flow. This Hold would upgrade to Buy if the stock pulled back toward the $275-$285 zone (implying roughly 14x-15x forward EPS) or if two consecutive quarters confirmed operating margins above 16% with FCF turning positive after capex; it would downgrade to Sell on any new impairment charge or if forward EPS estimates fell below $18.81 (the low end of the analyst range). Verdict: fairly valued on forward earnings, expensive on sales and book — a quality franchise priced for a recovery that is only one quarter old.
Sign up to view all
APD 12-Month Price Forecast
APD is a high-quality, low-beta (0.669) industrial gas franchise whose earnings are normalizing faster than its balance sheet, and at $316.53 the stock sits just 2.3% below its $324.00 52-week high after an 8.20% one-month surge against SPY's -2.26%. The forward PE of 20.4x is reasonable for a contracted, take-or-pay business, but the 4.77x P/S and 4.34x P/B leave little asset-based cushion if the recovery stalls, and the 8.7% upside to the $344.10 average target is modest relative to the 13.1% downside to the $275 low target. The helium crisis is a genuine pricing tailwind for the world's largest helium supplier, yet it cuts both ways if semiconductor customers cut output. I would upgrade to bullish on a pullback toward $275-$285 (roughly 14x-15x forward EPS) or on two consecutive quarters of 16%+ operating margins with positive post-capex free cash flow; I would downgrade to bearish on any new impairment charge or forward EPS estimates falling below $18.81.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Air Products & Chemicals's 12-month outlook, with a consensus price target around $344.57 and implied upside of +16.0% versus the current price.
Average Target
$344.57
24 analysts
Implied Upside
+16.0%
vs. current price
Analyst Count
24
covering this stock
Price Range
$275 - $375
Analyst target range
Coverage is robust with 21 analysts, and sentiment is decisively bullish: 15 Buy ratings, 9 Hold ratings, zero Sells, yielding a recommendation mean of 1.92 (buy) and a consensus recommendation of "buy." The average target price of $344.10 implies roughly 8.7% upside from the current $316.53, a moderate but positive signal that suggests analysts see the stock as fairly-to-attractively valued after its recent run rather than deeply undervalued. The consensus forward EPS estimate of $19.88 (range $18.81 to $21.15) and revenue estimate of $17.11 billion (range $16.40 billion to $17.95 billion) imply analysts expect a substantial step-up in both top-line growth and profitability from the trailing $12.49 billion revenue base — a forecast that hinges on megaproject ramp and volume recovery. The bullish tilt is reinforced by recent institutional actions: Barclays and RBC Capital both reiterated Overweight/Outperform ratings in early November following the Q4 beat, while Citigroup and UBS remain Neutral, indicating a split between growth-oriented and valuation-conscious analysts. The target range of $275.00 to $375.00 is wide — a spread of $100, or 32% of the current price — signaling meaningful disagreement about the company's trajectory. The high target of $375.00 (18.5% above current) likely assumes successful execution on clean hydrogen projects, helium pricing tailwinds from the supply crisis, and multiple expansion back toward the upper end of the historical PE band. The low target of $275.00 (13.1% below current) prices in continued project cost overruns, margin compression from capital intensity, or a helium supply disruption that hurts semiconductor customers more than it helps APD's pricing. The wide dispersion, combined with the absence of any Sell ratings, suggests analysts are uniformly constructive on the franchise but deeply divided on execution risk — a profile that argues for position sizing discipline given the binary nature of the megaproject outcome.
Bulls vs Bears: APD Investment Factors
The bull case currently carries stronger evidence: Q4 revenue growth of 12.27%, a return to a 16.0% operating margin from -66.3% in Q3, a forward PE of 20.4x at the low end of the normalized band, and a 15-Buy/0-Sell analyst consensus with 8.7% average upside all point to a recovery that is already visible in the numbers. The bear case is not about the franchise — gross margins have held in the 30.5%-32.8% range throughout — but about the balance sheet and cash flow: $4.2 billion of trailing capex, FCF of only $476.8 million, a 301% payout ratio, and debt-to-equity of 1.28 mean the dividend and the megaproject commitments depend on external financing. The single most important tension is whether the impairment cycle is genuinely over and the clean hydrogen/blue ammonia projects begin generating returns; Q4's 16.0% operating margin is the first real evidence for that, but one quarter does not resolve a multi-billion-dollar capital program. A secondary tension is helium: the supply crisis is a pricing tailwind for APD but a demand risk for its semiconductor customers, so the net effect could flip if chipmakers cut output. On balance, the data supports a constructive but execution-dependent view rather than an unqualified buy.
Bullish
- Q4 beat with raised guidance: Fiscal Q4 2026 revenue of $3.556 billion rose 12.27% year over year and was the strongest quarter of the fiscal year, with net income of $584.3 million and EPS of $2.62. Management raised guidance alongside the November 5 print, and the stock's +8.20% one-month move (versus SPY's -2.26%) shows the market repriced the recovery story in real time.
- Forward PE reasonable vs history: The forward PE of 20.4x on consensus EPS of $19.88 sits at the low end of APD's normalized 20x-27x band (Q1 2026 at 20.3x, Q2 2026 at 22.8x, Q3 2025 at 22.0x). The 26.4% YTD gain has come from earnings normalization rather than multiple expansion, leaving room for re-rating if estimates hold.
- Contracted on-site revenue base: Roughly 47% of revenue ($1.671 billion of the quarter's total) comes from on-site plants under long-term take-or-pay contracts, with merchant gases at $1.387 billion providing the volume upside cited in the Q4 beat. This mix underpins gross margin stability — 32.1%, 31.1%, 32.8%, and 30.5% across the last four quarters — even through the impairment period.
- Helium scarcity strengthens pricing power: As the world's largest helium supplier, APD benefits from the Middle East conflict-driven supply crisis that has exposed semiconductor customers' dependence on a single route for roughly 30% of helium. Scarcity supports pricing and volumes in the merchant segment, a tailwind that persists even if the conflict de-escalates.
Bearish
- Impairment-driven earnings distortion: The Q3 2026 loss of $1.441 billion (driven by $2.89 billion of other expenses) dragged trailing net margin to 4.10%, operating margin to -0.31%, and ROE to 3.73% versus 11.4% in fiscal Q4 2024. The trailing PE of 116.4x and negative PEG of -0.50 are artifacts of this, meaning the entire valuation case rests on normalized earnings actually materializing.
- Dividend not covered by free cash flow: TTM free cash flow of just $476.8 million against roughly $1.6 billion of annual dividends produces a 0.77% FCF yield and a 301% payout ratio on trailing earnings. The 2.59% yield is currently funded partly by balance-sheet capacity, a fragile arrangement if project returns disappoint.
- Heavy leverage and capital intensity: Debt-to-equity of 1.28 and total debt-to-capitalization of 56.1% reflect megaproject spending, with $849 million of capex in Q4 alone and $4.2 billion over the trailing four quarters. The current ratio of 1.07 is thin, and interest coverage of 8.5x leaves less cushion than the investment-grade rating implies.
- Premium on sales and book metrics: Price-to-sales of 4.77x and EV/sales of 6.95x sit well above the 1.5x-2.5x typical chemical-sector range, while price-to-book of 4.34x is near the top of APD's own 3.6x-4.9x historical band. On asset and revenue metrics the stock is not cheap — only the earnings multiple looks reasonable.
APD Technical Analysis
APD is in a sustained uptrend, with the current price of $316.53 sitting at roughly 92% of its 52-week range (low of $229.11, high of $324.00) and up 20.34% over the trailing year versus a 12.27% gain for SPY, a relative-strength advantage of 8.07 percentage points. The stock has recovered decisively from its 52-week low, having rallied approximately 38% off that trough, and the year-to-date gain of 26.37% against SPY's 10.62% underscores genuine market leadership rather than beta-driven drift. Trading just $7.47 (about 2.3%) below the 52-week high signals momentum is intact but leaves limited near-term headroom before resistance is tested. Recent momentum is accelerating rather than fading: the 1-month change of +8.20% is the strongest of the short-term windows and far outpaces the 3-month gain of just 2.45%, indicating a sharp re-acceleration in November after a summer-to-fall consolidation. That 1-month surge also dwarfs the 6-month change of 7.16%, meaning essentially all of the half-year gain was earned in the last four weeks — a burst of buying pressure that coincided with the November 5 earnings beat and raised guidance. The relative-strength reading of 10.46 points over one month versus SPY's -2.26% decline confirms this is idiosyncratic strength, though such a steep short-term move raises the risk of near-term mean reversion or profit-taking. Key resistance sits at the $324.00 52-week high; a clean breakout would confirm the uptrend and likely open a new leg higher, while support is anchored at the $229.11 52-week low with intermediate support around the $270-$280 zone where the stock repeatedly consolidated in June and September-October. The beta of 0.669 is notably defensive — roughly 33% less volatile than the market — which supports larger position sizing for risk-parity purposes but also means the 8.2% monthly move is unusually large for this name and may reflect event-driven repricing rather than a durable change in volatility regime. The maximum drawdown of -13.0% over the period is modest for an industrial, consistent with the low-beta profile.
Beta
0.67
0.67x market volatility
Max Drawdown
-13.0%
Largest decline past year
52-Week Range
$229-$324
Price range past year
Annual Return
+18.3%
Cumulative gain past year
| Period | APD Return | S&P 500 |
|---|---|---|
| 1m | -1.8% | -9.7% |
| 3m | -2.6% | -9.9% |
| 6m | +2.6% | -7.5% |
| 1y | +18.3% | +4.7% |
| ytd | +18.6% | +1.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
APD Fundamental Analysis
Revenue is growing at a healthy clip: fiscal Q4 2026 revenue of $3.556 billion rose 12.27% year over year, and the trailing four-quarter total of roughly $12.49 billion (Q1 $3.103B, Q2 $3.172B, Q3 $3.161B, Q4 $3.556B) shows sequential acceleration into the fiscal year-end, with Q4 the strongest quarter of the year. The segment mix of $1.671 billion on-site, $1.387 billion merchant, and $103 million sale of equipment highlights that roughly 47% of revenue comes from contracted on-site plants — the most stable, recurring portion of the business — while merchant gases provide the volume-driven upside cited in the Q4 beat. The 12.27% growth rate is well above the low-single-digit growth typical of mature industrial gas peers, suggesting the company is capturing both volume recovery and pricing, which materially strengthens the investment case if sustained. Profitability is more nuanced: Q4 net income of $584.3 million on a 16.4% net margin and 30.5% gross margin looks solid, but the trailing figures are distorted by a Q3 2026 loss of $1.441 billion (driven by $2.89 billion in other expenses, likely a project impairment) that dragged trailing net margin to 4.10% and trailing operating margin to -0.31%. Gross margin has been remarkably stable across quarters — 32.1% in Q1, 31.1% in Q2, 32.8% in Q3, and 30.5% in Q4 — indicating the underlying business economics are intact and the losses are non-operating in nature. The key question is whether the impairment cycle is now behind the company; the Q4 return to a 16.0% operating margin (versus -66.3% in Q3) suggests normalization, but the trailing ROE of 3.73% and ROA of 4.80% remain depressed versus the 11.4% ROE the company posted in fiscal Q4 2024. The balance sheet carries meaningful leverage: debt-to-equity of 1.28 and total debt-to-capitalization of 56.1% reflect the heavy capital spending on megaprojects, with capital expenditures of $849 million in Q4 alone and $4.2 billion across the trailing four quarters. Free cash flow is thin relative to the capital program — TTM FCF of $476.8 million against a $61.99 billion market cap implies a FCF yield of just 0.77%, and the dividend payout ratio of 301% on trailing earnings (2.59% yield) is only covered because of the impairment distortion; on a cash basis, dividends of roughly $1.6 billion annually exceed free cash flow, meaning the dividend is currently funded partly by balance-sheet capacity. The current ratio of 1.07 is adequate but not comfortable, and with interest coverage of 8.5x on the most recent quarter, the company retains investment-grade headroom — but the capital intensity means external financing dependence remains a genuine risk if project returns disappoint.
Quarterly Revenue
$3.6B
2026-09
Revenue YoY Growth
+12.3%
YoY Comparison
Gross Margin
30.5%
Latest Quarter
Free Cash Flow
$476800000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is APD Overvalued?
Because trailing net income is positive but heavily distorted by the Q3 impairment, the trailing PE of 116.4x is economically meaningless and I therefore lead with the forward PE of 20.4x as the primary metric, cross-checked against EV/EBITDA and price-to-sales. The gap between the 116.4x trailing and 20.4x forward multiple is enormous and implies the market expects earnings to normalize dramatically — consistent with consensus EPS estimates of $19.88 for the forward period versus the near-zero trailing EPS of $0.0086. That forward PE of 20.4x on $19.88 of expected EPS is the valuation anchor investors should use, and it implies the market is pricing a full recovery to pre-impairment profitability. Against the specialty chemicals industry, APD's 4.77x price-to-sales and 6.95x EV/sales sit at a premium to typical chemical-sector multiples in the 1.5x-2.5x P/S range, reflecting the contracted, recurring nature of industrial gas revenue and the company's hydrogen/helium franchise. The 4.34x price-to-book is elevated versus a sector norm nearer 2x, and the 13.24x price-to-cash-flow is rich, but the 20.4x forward PE is actually reasonable for a quality industrial gas compounder that historically traded in the low-to-mid 20s — suggesting the premium is concentrated in asset-based and sales-based metrics rather than earnings. The negative PEG ratio of -0.50 is a mechanical artifact of the impairment-driven earnings base and should be disregarded. Historically, APD's PE has ranged from roughly 8.5x (Q4 2024, an unusually strong earnings quarter) to over 3,000x (Q4 2025, near-zero earnings), with the more normal quarters clustering in the 20x-27x band (Q1 2026 at 20.3x, Q2 2026 at 22.8x, Q3 2025 at 22.0x). The current forward PE of 20.4x sits at the low end of that normalized band, which is constructive — the market is not pricing in heroic multiple expansion, and the stock's 26.4% YTD gain has been driven by earnings recovery rather than re-rating. However, the price-to-sales ratio of 4.77x and price-to-book of 4.34x are near the upper end of the stock's own historical range (P/S has ranged from about 14.5x on a different revenue base to over 22x in distorted periods, and P/B from 3.6x to 4.9x), so on asset and revenue metrics the stock is not cheap — the valuation case rests entirely on the earnings normalization materializing.
PE
116.4x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 20x~30x
vs. Industry Avg
31.4x
Industry PE ~31.4x*
EV/EBITDA
102.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the gap between capital commitments and cash generation. Trailing four-quarter capex of $4.2 billion against TTM free cash flow of $476.8 million means the $1.6 billion annual dividend is not covered by internally generated cash, producing a 301% payout ratio and a 0.77% FCF yield on the $62 billion market cap. Debt-to-equity of 1.28 and total debt-to-capitalization of 56.1% reflect this funding structure, and with a current ratio of 1.07 and interest coverage of 8.5x, a further impairment or project delay would force either higher leverage or a dividend reset. Earnings volatility is already extreme — quarterly EPS has swung from -$7.77 (Q2 2025) to -$6.46 (Q3 2026) to +$2.62 (Q4 2026) — and the trailing ROE of 3.73% versus 11.4% in fiscal Q4 2024 shows how far profitability has to travel to normalize. Market and competitive risks are dominated by valuation compression. The forward PE of 20.4x is fair, but price-to-sales of 4.77x and EV/sales of 6.95x sit at a premium to the 1.5x-2.5x chemical norm, and price-to-book of 4.34x is near the top of APD's own 3.6x-4.9x range, so any earnings disappointment would hit a stock with little asset-based support. The beta of 0.669 is defensive, but the stock's +8.20% one-month move against SPY's -2.26% is unusually large for this name and raises mean-reversion risk, particularly with the price just 2.3% below the $324.00 52-week high. The helium crisis cuts both ways: it strengthens APD's pricing as the largest supplier, but if semiconductor customers cut output in response to supply constraints, merchant volumes fall — and Citigroup and UBS remaining Neutral despite the Q4 beat shows the market has not resolved this. The worst-case scenario is a renewed megaproject impairment combined with a helium-driven semiconductor demand slowdown: Q3 2026 already demonstrated the damage, with $2.89 billion of other expenses producing a $1.441 billion quarterly loss and a -66.3% operating margin. From the current $316.53, a retest of the $275 analyst low target implies roughly -13%, while a full round-trip to the $229.11 52-week low implies approximately -28%; the stock's -13.0% maximum drawdown over the past 180 days shows how quickly such a move can occur, and a repeat impairment would likely push toward the lower end of that range.
FAQ
The risk/reward is balanced rather than compelling at $316.53. Upside to the $344.10 average analyst target is about 8.7%, while downside to the $275 low target is roughly 13.1% and a full retest of the $229.11 52-week low would be about -27.6% — an unfavorable ratio for a fresh full position. The quality case is real: 15 Buy ratings versus zero Sells, a forward PE of 20.4x at the low end of the normalized 20x-27x band, and Q4 2026 revenue growth of 12.27% with a 16.0% operating margin. But the stock sits just 2.3% below its $324.00 52-week high after an 8.20% one-month surge against SPY's -2.26%, and free cash flow of $476.8 million does not cover the dividend. It is a reasonable buy for long-horizon investors who can scale in on weakness toward $275-$285 (roughly 14x-15x forward EPS), and a less attractive entry for anyone buying the momentum at current levels.

